David Roman, an analyst from Goldman Sachs, maintained the Buy rating on LivaNova (LIVN – Research Report). The associated price target remains the same with $55.00.
David Roman’s rating is based on a combination of factors that suggest a positive outlook for LivaNova. The company has shown potential for sustained organic growth in its core business, driven by new product upgrades and market share gains, particularly in the Oxygenators segment. Additionally, there is a recovery in the Neuromodulation business outside the U.S., which is expected to contribute to near-term growth.
Roman also highlights the importance of LivaNova’s ability to maintain strong performance in its Cardiopulmonary segment, which accounts for a significant portion of sales. The company’s guidance for 2025 suggests continued growth, supported by the successful upgrade cycle of the Essenz Heart Lung Machine. Furthermore, clarity on pipeline development and consistent earnings performance are seen as crucial for driving future stock momentum.
According to TipRanks, Roman is a 3-star analyst with an average return of 2.8% and a 55.56% success rate. Roman covers the Healthcare sector, focusing on stocks such as Stryker, Teladoc, and LivaNova.
In another report released on February 26, Robert W. Baird also maintained a Buy rating on the stock with a $60.00 price target.